Other Panels
Quad RPP
Respiratory Pathogen Panel
One Swab. Four Respiratory Viruses. Clear Answers.
Quad RPP is a multiplex PCR test that detects SARS-CoV-2 (COVID-19), Influenza A, Influenza B, and RSV from a single swab, giving clinicians the specific answer they need to guide treatment and infection control.
Key Benefits
-
Four Viruses, One Swab
Detects SARS-CoV-2, Influenza A, Influenza B, and RSV in a single test, including co-infections.
-
Guides Antiviral Therapy
Influenza and COVID-19 have different antivirals and treatment windows, so knowing which virus is present guides the right prescription.
-
Supports Infection Control
Accurate identification informs isolation decisions, especially for high-risk patients and congregate settings.
-
PCR Sensitivity
Detects low viral loads that rapid antigen tests can miss, including early in infection.
Why Identifying the Virus Matters
COVID-19, influenza, and RSV often present the same way: fever, cough, body aches, and fatigue. A physical exam can't reliably tell them apart, yet the next step depends on which virus is present. Influenza antivirals work best when started within about 48 hours of symptom onset, COVID-19 has its own antivirals with different eligibility criteria and treatment windows, and RSV carries added risk for infants and older adults. When these viruses circulate at the same time, one PCR test identifies which is present, including co-infections, so clinicians can treat and advise patients accurately.
PCR vs. Rapid Antigen Testing
Rapid antigen tests offer speed, but they are less sensitive than PCR, so a negative result may still need confirmation. PCR can identify infection in its earliest stages, often before symptoms peak and viral levels are high enough for an antigen test to detect. Quad RPP detects all four viruses from one swab with molecular sensitivity, giving clinicians a reliable result that guides targeted treatment from the start.
Test Specifications
| Test Name | Quad RPP (Respiratory Pathogen Panel) |
|---|---|
| Methodology | Multiplex PCR molecular detection |
| Specimen Type | Nasal swab in viral transport medium |
| Targets | SARS-CoV-2 (COVID-19), Influenza A, Influenza B, RSV |
| Use Case | Patients with symptoms of acute respiratory infection, including when COVID-19, influenza, and RSV are circulating at the same time |
| Turnaround | In-house: same day. Sent to SoftCell: typically 24 to 48 hours from receipt. |
| Availability | Run in your own lab, or send out to SoftCell Laboratories, a Doc Lab-owned company. |
Built for Care Across Specialties
Quad RPP fits naturally in multi-specialty, primary care, urgent care, and pediatric settings, where patients with respiratory symptoms are a regular part of fall and winter care. In long-term care, where residents are especially vulnerable and outbreaks can spread quickly, identifying the specific virus guides treatment and supports infection control. It's also a strong addition for hospital labs and independent reference labs looking to offer respiratory testing to the clinicians they serve.
Set Up or Send Out
Doc Lab supports labs adding Quad RPP from start to finish, including equipment setup, method validation, staff training, and 24/7 clinical and technical support. Prefer to send it out? SoftCell Laboratories, a Doc Lab-owned company, accepts samples, so you can choose the option that fits your lab.
Let's talk
Ready to Move Beyond Rapid Antigen Tests?
Quad RPP detects COVID-19, influenza, and RSV from one swab, with the sensitivity rapid antigen tests can't match. Let's discuss whether Quad RPP fits your lab.